Table 1.

Smoothened inhibitors currently in clinical trials for cancer

Drug	Sponsor	Indications	Phases
GDC-0449	Genentech, Curis, Roche	Advanced solid tumors, BCC, breast, chondrosarcoma, colorectal, gastric, Glioblastoma multiforme, medulloblastoma, multiple myeloma, ovarian, Pancreatic, prostate sarcoma, small cell lung	Phase II
LDE-225	Novartis	Advanced solid tumors, BCC, chronic myeloid leukemia, pancreatic	Phase I, II
BMS-833923 (XL139)	Bristol-Myers Squibb, Exelixis	Advanced solid tumors, BCC, chronic myeloid leukemia, esophageal, gastric, multiple myeloma, small cell lung	Phase I, II
IPI-926	Infinity	Advanced solid tumors, chondrosarcoma, head and neck, myelofibrosis, pancreatic	Phase I, II
PF-04449913	Pfizer	Advanced solid tumors, hematologic malignancies	Phase I
LEQ-506	Novartis	Advanced solid tumors	Phase I
TAK-441	Millenium	Advanced solid tumors	Phase I
Itraconazole		BCC, metastatic prostate cancer, non-small cell lung cancer	Phase II

Note: As listed on clinicaltrials.gov on November 9, 2011.

Abbreviation: BCC, basal cell carcinoma.